U.S. researchers have successfully eliminated patient stress, long-term neural implants that act as neural pacemakers, and rehabilitate neurotransmitters connected by negative thoughts.
A team at the University of California, San Francisco (UCSF) said the study was “extremely successful” in a scientific effort to treat dementia using high-tech electronic devices. The study is published in Natural Notes.
Andrew Krystal, professor of psychiatry at UCSF, said: “We have developed a comprehensive approach to treatment that has successfully addressed our patient’s frustration by not recognizing medical care by recognizing and changing the area in his brain that is uniquely connected to his symptoms.”
At a teleconference before the press release, the 36-year-old patient, who only gave her name as Sarah, said the transplant had changed her life after five years so frustrated that she would not respond to any medication or medication. . “Every day,” she says, “I felt that I had committed suicide. “I was at the end of the line.”
Almost as soon as it was inserted into his brain, the device provided relief, which lasted a year. Recognizing neural phenomena linked to irrational thoughts, which in the past have caused frustration, its electrons provide frequent beats, electrical repairs and “poof… Circling stops,” as Sarah put it.
Dementia (DBS) has recently been a treatment for epilepsy and Parkinson’s disease but has not been effective in combating depression, which affects 280m people worldwide according to the World Health Organization. About 30 percent of depressed patients do not respond well to medical attention.
The problem with using neuro-electronics for depression is that scientists do not know much about the neurological mechanisms involved in the disorder. The main secret of the UCSF group was a “biomarker” that signal the onset of depression, a type of neural phenomenon in a part of the brain called the amygdala that responds to a threat.
The DBS tool used in this study was adapted from the one used to treat epilepsy. When it detects a biomarker in the amygdala, it transmits a small amount of light to another area, the ventral striatum, which is part of the brain’s reward and excitement. This immediately removes the emotional unnecessary.
Sameer Sheth, a neurologist at Baylor College of Medicine in Houston who has not participated in UCSF research, is also trying another clinical trial to alleviate frustration and is about to publish positive results. He also said the two projects are demonstrating a research approach to creating an “independent approach to psychiatric care”, based on the stimulus of other brain circuits.
While the approach was promising, Sarah was the first patient in the first cases to be published, UCSF assistant professor of psychiatry Katherine Scangos warned. Scangos has enrolled two other people with severe depression to take part in the study and the target is all 12 patients.
“We need to see how the scales vary between patients and repeat this activity several times,” he said, “and we need to see if the biomarker virus or the brain area changes over time as treatment progresses.”
Placing a plant under a skull with electrons reaching deep into the brain is expensive, dangerous and dangerous. Most of the blood-borne pathogens are well understood, “we hope to find residual weapons that can be used with non-depressive drugs,” Scangos said.